San Francisco – March 22, 2017 – Cooley advised the underwriter on Anthera’s $15 million shelf-takedown offering of 30,000,000 shares of common stock and two tranches of warrants to purchase up to an aggregate of 60,000,000 shares. The underwriter has a 30-day option to purchase up to an additional 4,500,000 shares of common stock and/or warrants to purchase up to an additional 9,000,000 shares of common stock at the public offering prices.
Rodman & Renshaw, a unit of HC Wainwright & Co., acted as the sole book-running manager for the offering.
Anthera, which trades on The NASDAQ Global Market as “ANTH,” is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.